Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive ...

For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP breathing machines, surgery, a dental mouthpiece and even an implantable pac ...

Data from recent research involving 400,000 participants revealed that eating cheese influenced 23 biomarkers linked to sleep apnea.

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Sleep apnea impacts about 30 million American adults, making it a common sleep disorder. But while plenty of people struggle with symptoms like loud snoring, daytime sleepiness, and morning ...

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

Though past research has focused on the health benefits of cheese, the new data examined its direct relationship to the ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

What many dismiss as a mere nighttime nuisance often signals deeper health issues requiring medical attention. While snoring ...

Major health insurance providers in India — both public and private — exclude sleep disorders from their plans. This coverage ...